273 related articles for article (PubMed ID: 21659470)
21. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion.
Hesse LM; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):100-2. PubMed ID: 11159797
[TBL] [Abstract][Full Text] [Related]
22. Examination of purported probes of human CYP2B6.
Ekins S; VandenBranden M; Ring BJ; Wrighton SA
Pharmacogenetics; 1997 Jun; 7(3):165-79. PubMed ID: 9241656
[TBL] [Abstract][Full Text] [Related]
23. Effects of the selected cytochrome P450 oxidoreductase genetic polymorphisms on cytochrome P450 2B6 activity as measured by bupropion hydroxylation.
Lv J; Hu L; Zhuo W; Zhang C; Zhou H; Fan L
Pharmacogenet Genomics; 2016 Feb; 26(2):80-7. PubMed ID: 26580670
[TBL] [Abstract][Full Text] [Related]
24. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6.
Mo SL; Liu YH; Duan W; Wei MQ; Kanwar JR; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):730-53. PubMed ID: 19702527
[TBL] [Abstract][Full Text] [Related]
25. CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
Leger P; Dillingham R; Beauharnais CA; Kashuba AD; Rezk NL; Fitzgerald DW; Pape JW; Haas DW
J Infect Dis; 2009 Sep; 200(6):955-64. PubMed ID: 19659438
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.
Holzinger ER; Grady B; Ritchie MD; Ribaudo HJ; Acosta EP; Morse GD; Gulick RM; Robbins GK; Clifford DB; Daar ES; McLaren P; Haas DW
Pharmacogenet Genomics; 2012 Dec; 22(12):858-67. PubMed ID: 23080225
[TBL] [Abstract][Full Text] [Related]
27. Multiple novel nonsynonymous CYP2B6 gene polymorphisms in Caucasians: demonstration of phenotypic null alleles.
Lang T; Klein K; Richter T; Zibat A; Kerb R; Eichelbaum M; Schwab M; Zanger UM
J Pharmacol Exp Ther; 2004 Oct; 311(1):34-43. PubMed ID: 15190123
[TBL] [Abstract][Full Text] [Related]
28. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity.
Faucette SR; Hawke RL; Lecluyse EL; Shord SS; Yan B; Laethem RM; Lindley CM
Drug Metab Dispos; 2000 Oct; 28(10):1222-30. PubMed ID: 10997944
[TBL] [Abstract][Full Text] [Related]
29. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
[TBL] [Abstract][Full Text] [Related]
30. CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants.
Hesse LM; Venkatakrishnan K; Court MH; von Moltke LL; Duan SX; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2000 Oct; 28(10):1176-83. PubMed ID: 10997936
[TBL] [Abstract][Full Text] [Related]
31. Metabolism of efavirenz and 8-hydroxyefavirenz by P450 2B6 leads to inactivation by two distinct mechanisms.
Bumpus NN; Kent UM; Hollenberg PF
J Pharmacol Exp Ther; 2006 Jul; 318(1):345-51. PubMed ID: 16611850
[TBL] [Abstract][Full Text] [Related]
32. Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Manosuthi W; Sukasem C; Lueangniyomkul A; Mankatitham W; Thongyen S; Nilkamhang S; Manosuthi S; Sungkanuparph S
Antimicrob Agents Chemother; 2013 Feb; 57(2):1019-24. PubMed ID: 23254426
[TBL] [Abstract][Full Text] [Related]
33. Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
Haas DW; Gebretsadik T; Mayo G; Menon UN; Acosta EP; Shintani A; Floyd M; Stein CM; Wilkinson GR
J Infect Dis; 2009 Mar; 199(6):872-80. PubMed ID: 19239339
[TBL] [Abstract][Full Text] [Related]
34. CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
Kwara A; Lartey M; Sagoe KW; Rzek NL; Court MH
Br J Clin Pharmacol; 2009 Apr; 67(4):427-36. PubMed ID: 19371316
[TBL] [Abstract][Full Text] [Related]
35. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients.
Cabrera SE; Santos D; Valverde MP; Domínguez-Gil A; González F; Luna G; García MJ
Antimicrob Agents Chemother; 2009 Jul; 53(7):2791-8. PubMed ID: 19433561
[TBL] [Abstract][Full Text] [Related]
36. The influence of sex, ethnicity, and CYP2B6 genotype on bupropion metabolism as an index of hepatic CYP2B6 activity in humans.
Ilic K; Hawke RL; Thirumaran RK; Schuetz EG; Hull JH; Kashuba AD; Stewart PW; Lindley CM; Chen ML
Drug Metab Dispos; 2013 Mar; 41(3):575-81. PubMed ID: 23238783
[TBL] [Abstract][Full Text] [Related]
37. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
Ogburn ET; Jones DR; Masters AR; Xu C; Guo Y; Desta Z
Drug Metab Dispos; 2010 Jul; 38(7):1218-29. PubMed ID: 20335270
[TBL] [Abstract][Full Text] [Related]
38. Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations.
Xu BY; Guo LP; Lee SS; Dong QM; Tan Y; Yao H; Li LH; Lin CK; Kung HF; He ML
World J Gastroenterol; 2007 Apr; 13(14):2100-3. PubMed ID: 17465455
[TBL] [Abstract][Full Text] [Related]
39. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Kharasch ED; Mitchell D; Coles R
J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
[TBL] [Abstract][Full Text] [Related]
40. Allele and genotype frequencies of cytochrome P450 2B6 gene in a Mongolian population.
Davaalkham J; Hayashida T; Tsuchiya K; Gatanaga H; Nyamkhuu D; Oka S
Drug Metab Dispos; 2009 Oct; 37(10):1991-3. PubMed ID: 19581387
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]